| __timestamp | MannKind Corporation | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 94231000 |
| Thursday, January 1, 2015 | 29674000 | 146394000 |
| Friday, January 1, 2016 | 14917000 | 188272000 |
| Sunday, January 1, 2017 | 14118000 | 166707000 |
| Monday, January 1, 2018 | 8737000 | 401843000 |
| Tuesday, January 1, 2019 | 6900000 | 560909000 |
| Wednesday, January 1, 2020 | 6248000 | 722343000 |
| Friday, January 1, 2021 | 12312000 | 771182000 |
| Saturday, January 1, 2022 | 19721000 | 877090000 |
| Sunday, January 1, 2023 | 31283000 | 877387000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. has consistently outpaced MannKind Corporation in R&D investment. From 2014 to 2023, Sarepta's R&D expenses surged by over 830%, peaking in 2023 with a staggering $877 million. In contrast, MannKind's R&D spending saw a decline, dropping by nearly 70% from its 2014 high of $100 million to just $31 million in 2023.
This trend highlights Sarepta's aggressive pursuit of innovation, likely driven by its focus on developing cutting-edge therapies for rare diseases. Meanwhile, MannKind's reduced R&D investment may reflect strategic shifts or financial constraints. As the biotech landscape evolves, these spending patterns offer a glimpse into each company's priorities and potential future breakthroughs.
Johnson & Johnson or MannKind Corporation: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Merck & Co., Inc. vs MannKind Corporation
Research and Development: Comparing Key Metrics for Insmed Incorporated and MannKind Corporation
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Lantheus Holdings, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.: Strategic Focus on R&D Spending
Ascendis Pharma A/S vs MannKind Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and MannKind Corporation
Analyzing R&D Budgets: MorphoSys AG vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Supernus Pharmaceuticals, Inc. and MannKind Corporation
Iovance Biotherapeutics, Inc. or MannKind Corporation: Who Invests More in Innovation?